Buprenorphine and Taletrectinib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Taletrectinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines can affect the timing of your heartbeat. Doctors call this QT prolongation. Buprenorphine (used for pain or opioid treatment) and taletrectinib (a cancer medicine) can each nudge that timing, and taking them together may add up. In rare cases, a longer QT can lead to a dangerous irregular heartbeat.
The good news is that this is a known, manageable concern. This warning is based mostly on how the drugs work rather than lots of real-world reports. Your care team can keep you safe by checking your heart tracing (ECG) and blood minerals, and by adjusting things as needed. Please don't stop either medicine on your own, just talk with your doctor or pharmacist.
Effect: Additive QTc prolongation, with increased theoretical risk of ventricular tachyarrhythmias (torsades de pointes) and sudden death.
Mechanism: Both agents can prolong the QT interval; combined use is additive on cardiac repolarization. Neither is a prodrug relevant here.
Evidence: Theoretical; severity major. Onset unspecified.
Management:
- Avoid concomitant use where possible.
- If unavoidable, obtain baseline ECG and electrolytes, then monitor periodically per risk factors.
- Correct K+/Mg2+; assess for bradyarrhythmias, HF, congenital long QT.
- Withhold taletrectinib if QTc greater than 500 msec or change from baseline greater than 60 msec; resume at same/reduced dose or discontinue per severity. Give taletrectinib on an empty stomach.
What happens
Increased risk of QT interval prolongation and torsade de pointes
Interaction Deep Dive
Do not use taletrectinib together with other agents recognized as having the capacity to lengthen the QTc interval, because doing so can heighten the risk of QTc interval prolongation, which in turn can raise the likelihood of ventricular tachyarrhythmias (for example, torsades de pointes) or sudden death. When the combination is unavoidable, modify how often monitoring is performed according to recommendations. Hold taletrectinib when the QTc interval exceeds 500 msec, or when a change from baseline greater than 60 msec produces QTc interval prolongation. Obtain ECGs and check electrolytes before giving taletrectinib, and repeat these periodically during therapy as clinically warranted. The monitoring frequency should be tailored to risk factors including known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure, and coadministered drugs linked to QTc interval prolongation. Give taletrectinib on an empty stomach. Depending on severity, withhold the drug and then resume it at the same or a lowered dose, or discontinue it permanently1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
Your care team can manage this safely. Here is what usually happens:
- Keep taking both as prescribed unless your doctor tells you otherwise.
- Your team may check a baseline ECG (heart tracing) and blood electrolytes like potassium and magnesium, then recheck periodically.
- They may monitor you more closely if you have heart rhythm problems, heart failure, or a family history of long QT.
- The taletrectinib dose may be adjusted and individualized, and it is taken on an empty stomach.
Tell your pharmacist or doctor about any fainting, dizziness, palpitations, or irregular heartbeat right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) Within the pooled safety population, among the 351 patients who had at least one ECG evaluation after baseline, 13% showed an increase in QTcF (QT interval corrected using the Fridericia formula) exceeding 60 msec relative to baseline following taletrectinib administration, and 2.6% had a QTcF rise to more than 500 msec. In total, 3.4% of patients experienced Grade greater than and equal to 3 QTc interval prolongation. The median interval between the first taletrectinib dose and the appearance of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). QTc prolongation resulted in dose interruption and dose reduction, each occurring in 2.8% of patients receiving taletrectinib 1.
Common questions
Can I take Buprenorphine and Taletrectinib together?
Combining buprenorphine and taletrectinib can add up to affect your heart rhythm (QT prolongation), so keep taking both as prescribed while your care team monitors your ECG and electrolytes and adjusts as needed. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Taletrectinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Taletrectinib interaction managed?
Your care team can manage this safely. Here is what usually happens: Keep taking both as prescribed unless your doctor tells you otherwise. Your team may check a baseline ECG (heart tracing) and blood electrolytes like potassium and magnesium, then recheck periodically. They may monitor you more closely if you have heart rhythm problems, heart failure, or a family history of long QT. The taletrect… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Buprenorphine or Taletrectinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: IBTROZI(TM) oral capsules, taletrectinib oral capsules. Nuvation Bio Inc. (per Manufacturer), Burlington, MA, 2025. DailyMed
Keep reading about Buprenorphine
Keep reading about Taletrectinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist